These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 34958235

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Patient Outcomes, Health Care Resource Use, and Costs Associated with High Versus Low HEDIS Asthma Medication Ratio.
    Luskin AT, Antonova EN, Broder MS, Chang E, Raimundo K, Solari PG.
    J Manag Care Spec Pharm; 2017 Nov; 23(11):1117-1124. PubMed ID: 29083971
    [Abstract] [Full Text] [Related]

  • 23. Inpatient Admissions and Costs Associated with Persistent Use of Dalfampridine Extended-Release in Multiple Sclerosis: A Claims Database Analysis.
    Guo A, Niyazov A, Macaulay D, Terasawa E, Schmerold L, Wu EQ, Krieger S.
    J Manag Care Spec Pharm; 2017 Jul; 23(7):771-780. PubMed ID: 28650249
    [Abstract] [Full Text] [Related]

  • 24. The use of short-acting bronchodilators and cost burden of asthma across Global Initiative for Asthma-based severity levels: Insights from a large US commercial and managed Medicaid population.
    Pollack M, Gandhi H, Tkacz J, Lanz M, Lugogo N, Gilbert I.
    J Manag Care Spec Pharm; 2022 Aug; 28(8):881-891. PubMed ID: 35708342
    [Abstract] [Full Text] [Related]

  • 25. Healthcare resource utilization and cost among patients with type 1 diabetes in the United States.
    Simeone JC, Shah S, Ganz ML, Sullivan S, Koralova A, LeGrand J, Bushman J.
    J Manag Care Spec Pharm; 2020 Nov; 26(11):1399-1410. PubMed ID: 33119443
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. The cost impact of disease progression to metastatic castration-sensitive prostate cancer.
    Trinh QD, Chaves LP, Feng Q, Zhu J, Sandin R, Abbott T.
    J Manag Care Spec Pharm; 2022 May; 28(5):544-554. PubMed ID: 35471070
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Economic burden of major bleeding events in commercially insured patients with von Willebrand disease based on claims data from the United States.
    Lu M, Oladapo A, Wu Y, Farahbakhshian S, Ewenstein B.
    J Manag Care Spec Pharm; 2021 Feb; 27(2):175-185. PubMed ID: 33307935
    [Abstract] [Full Text] [Related]

  • 30. Perspective - The case for zero bleeds and drug bioequivalence in the treatment of congenital hemophilia A in 2021.
    Di Minno A, Spadarella G, Esposito S, Mathew P, Di Minno G, Mannucci PM.
    Blood Rev; 2021 Nov; 50():100849. PubMed ID: 34024681
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Annual health care resource utilization and cost among type 2 diabetes patients with newly recognized chronic kidney disease within a large U.S. administrative claims database.
    Folkerts K, Petruski-Ivleva N, Kelly A, Fried L, Blankenburg M, Gay A, Kovesdy CP.
    J Manag Care Spec Pharm; 2020 Dec; 26(12):1506-1516. PubMed ID: 33251992
    [Abstract] [Full Text] [Related]

  • 33. Measuring the impact of changing from standard half-life (SHL) to extended half-life (EHL) FVIII prophylaxis on health-related quality of life (HRQoL) in boys with moderate/severe haemophilia A: Lessons learned with the CHO-KLAT tool.
    Carcao M, Zunino L, Young NL, Dover S, Bouskill V, Hilliard P, Price VE, Blanchette VS.
    Haemophilia; 2020 Jan; 26(1):73-78. PubMed ID: 31865620
    [Abstract] [Full Text] [Related]

  • 34. Increased health care costs associated with new persistent opioid use after major surgery in opioid-naive patients.
    Brummett CM, Evans-Shields J, England C, Kong AM, Lew CR, Henriques C, Zimmerman NM, Sun EC.
    J Manag Care Spec Pharm; 2021 Jun; 27(6):760-771. PubMed ID: 33624534
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Incremental cost burden among patients with severe uncontrolled asthma in the United States.
    Burnette A, Wang Y, Rane PB, Chung Y, Princic N, Park J, Llanos JP, Lindsley AW, Ambrose CS.
    J Manag Care Spec Pharm; 2023 Jul; 29(7):825-834. PubMed ID: 37404066
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Terminal half-life of FVIII and FIX according to age, blood group and concentrate type: Data from the WAPPS database.
    Versloot O, Iserman E, Chelle P, Germini F, Edginton AN, Schutgens REG, Iorio A, Fischer K, Pharmacokinetic (PK) Expert Working Group of the International Prophylaxis Study Group (IPSG).
    J Thromb Haemost; 2021 Aug; 19(8):1896-1906. PubMed ID: 34013558
    [Abstract] [Full Text] [Related]

  • 39. Cost analysis of plasma-derived factor VIII/von Willebrand factor versus recombinant factor VIII for treatment of previously untreated patients with severe hemophilia A in the United States.
    Neufeld EJ, Sidonio RF, O'Day K, Runken MC, Meyer K, Spears J.
    J Med Econ; 2018 Aug; 21(8):762-769. PubMed ID: 29681200
    [Abstract] [Full Text] [Related]

  • 40. Prolonged oral corticosteroid treatment in patients with systemic lupus erythematosus: An evaluation of 12-month economic and clinical burden.
    Huang SP, DerSarkissian M, Gu YM, Duh MS, Wang MJ, Benson J, Vu J, Averell C, Bell CF.
    J Manag Care Spec Pharm; 2023 Apr; 29(4):365-377. PubMed ID: 36989451
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.